Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.


Prior case reports and observational studies indicate that intravenous immune globulin (IVIg) products may cause thromboembolic events (TEEs), leading the FDA to require a boxed warning in 2013. The effect of IVIg treatment on the risk of serious TEEs (acute myocardial infarction, ischemic stroke, or venous thromboembolism) was assessed using adverse event… (More)
DOI: 10.1002/ajh.24358


2 Figures and Tables